Osimertinib in NSCLC With Atypical EGFR -Activating Mutations: A Retrospective Multicenter Study.

Autor:	Ji J; City of Hope Comprehensive Cancer Center, Duarte, California.; UC Davis Comprehensive Cancer Center, Sacramento, California., Aredo JV; Stanford Cancer Institute, Stanford, California., Piper-Vallillo A; Massachusetts General Hospital Cancer Center, Boston, Massachusetts., Huppert L; UCSF Helen Diller Comprehensive Cancer Center, San Francisco, California., Rotow JK; Dana-Farber Cancer Institute, Boston, Massachusetts., Husain H; UCSD Moores Comprehensive Cancer Center, La Jolla, San Diego, California., Stewart S; UC Davis Comprehensive Cancer Center, Sacramento, California., Cobb R; Massachusetts General Hospital Cancer Center, Boston, Massachusetts., Wakelee HA; Stanford Cancer Institute, Stanford, California., Blakely CM; UCSF Helen Diller Comprehensive Cancer Center, San Francisco, California., Wong ML; UCSF Helen Diller Comprehensive Cancer Center, San Francisco, California., Gubens MA; UCSF Helen Diller Comprehensive Cancer Center, San Francisco, California., Madani MH; UC Davis Comprehensive Cancer Center, Sacramento, California., Digumarthy SR; Massachusetts General Hospital Cancer Center, Boston, Massachusetts., McCoach C; UCSF Helen Diller Comprehensive Cancer Center, San Francisco, California., Piotrowska Z; Massachusetts General Hospital Cancer Center, Boston, Massachusetts., Neal JW; Stanford Cancer Institute, Stanford, California., Riess JW; UC Davis Comprehensive Cancer Center, Sacramento, California.
Jazyk:	angličtina
Zdroj:	JTO clinical and research reports [JTO Clin Res Rep] 2023 Jan 10; Vol. 4 (3), pp. 100459. Date of Electronic Publication: 2023 Jan 10 (Print Publication: 2023).
DOI:	10.1016/j.jtocrr.2022.100459
Abstrakt:	Introduction: EGFR mutations drive a subset of NSCLC. Patients harboring the common EGFR mutations, deletion of exon 19 and L858R, respond well to osimertinib, a third-generation tyrosine kinase inhibitor. Nevertheless, the effect of osimertinib on NSCLC with atypical EGFR mutations is not well described. This multicenter retrospective study evaluates the efficacy of osimertinib among patients with NSCLC harboring atypical EGFR mutations. Methods: Patients with metastatic NSCLC treated with osimertinib, harboring at least one atypical EGFR mutation, excluding concurrent deletion of exon 19, L858R, or T790M mutations, from six U.S. academic cancer centers were included. Baseline clinical characteristics were collected. The primary end point was the time to treatment discontinuation (TTD) of osimertinib. Objective response rate by the Response Evaluation Criteria in Solid Tumors version 1.1 was also assessed. Results: A total of 50 patients with NSCLC with uncommon EGFR mutations were identified. The most frequent EGFR mutations were L861Q (40%, n = 18), G719X (28%, n = 14), and exon 20 insertion (14%, n = 7). The median TTD of osimertinib was 9.7 months (95% confidence interval [CI]: 6.5-12.9 mo) overall and 10.7 months (95% CI: 3.2-18.1 mo) in the first-line setting (n = 20). The objective response rate was 31.7% (95% CI: 18.1%-48.1%) overall and 41.2% (95% CI: 18.4%-67.1%) in the first-line setting. The median TTD varied among patients with L861Q (17.2 mo), G719X (7.8 mo), and exon 20 insertion (1.5 mo) mutations. Conclusions: Osimertinib has activity in patients with NSCLC harboring atypical EGFR mutations. Osimertinib activity differs by the type of atypical EGFR -activating mutation. (© 2023 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu